CDiP technology for reverse engineering of sporadic Alzheimer's disease

Area of Science:

• Neurogenetics
• Computational Biology
• Stem Cell Biology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder with complex, often unknown, causes for sporadic cases.
• Current treatments and preventative strategies for AD remain unconfirmed, highlighting the need for novel research approaches.
• Understanding the genetic underpinnings of AD at a granular level is crucial for developing effective interventions.

Purpose of the Study:

• To introduce and detail the cellular dissection of polygenicity (CDiP) technology for analyzing Alzheimer's disease genetics.
• To identify cellular-level genetic factors, potential therapeutic targets, and polygenes associated with Alzheimer's disease.
• To explore the application of CDiP in predicting real-world AD progression using large-scale cohort data.

Main Methods:

• Development and application of cellular dissection of polygenicity (CDiP) technology.
• Utilizing induced pluripotent stem cell (iPSC) cohorts for cellular genetic analysis.
• Performing cell genome-wide association studies (cell GWAS) and applying machine learning algorithms.
• Analysis of real-world data from Alzheimer's Disease Neuroimaging Initiative (ADNI) and Japanese ADNI (J-ADNI) cohorts.

Main Results:

• Identification of key genetic factors at the cellular level contributing to Alzheimer's disease.
• Discovery of potential therapeutic targets and a rare variant for disease stratification in AD.
• Development of polygenes capable of predicting real-world AD progression using cohort data.
• Demonstration of CDiP's utility in analyzing complex genetic architectures of neurodegenerative diseases.

Conclusions:

• Cellular dissection of polygenicity (CDiP) offers a novel approach to dissecting the genetic complexity of sporadic Alzheimer's disease.
• CDiP technology has successfully identified potential therapeutic targets and predictive biomarkers for AD.
• Future applications of CDiP hold promise for advancing our understanding and potentially eradicating Alzheimer's disease through reverse engineering its causes.